No, a patient should not take two Unisom tablets
The FDA-approved dosing for Unisom (doxylamine succinate 25 mg) is one tablet taken 30 minutes before bedtime, once daily, and patients should not exceed this dose 1.
Critical Dosing Information
The FDA drug label explicitly states: "take one tablet 30 minutes before going to bed; take once daily or as directed by a doctor" for adults and children 12 years and over 1. This is a clear directive that should not be exceeded without physician supervision.
Why Diphenhydramine/Antihistamines Are Not Recommended for Insomnia
While the question asks about Unisom (which contains doxylamine, not diphenhydramine as suggested in the expanded context), the evidence regarding first-generation antihistamines is highly relevant:
The American Academy of Sleep Medicine (2017) explicitly recommends against using diphenhydramine for treating insomnia in adults 2. This recommendation is based on moderate-quality evidence showing that harms outweigh benefits. The guideline applies the same logic to all over-the-counter antihistamine sleep aids.
Key Safety Concerns with Doubling the Dose
Rapid Tolerance Development
- Complete tolerance to sedative effects develops within 3-4 days of regular use 3
- By day 4, diphenhydramine at 50 mg twice daily showed no difference from placebo in objective sleepiness measures
- This means doubling the dose provides no sustained benefit
Dose-Dependent Toxicity
Toxicity data for diphenhydramine (structurally similar to doxylamine) shows clear dose-dependent risks 4:
- Mild symptoms (somnolence, anticholinergic effects): occur at therapeutic doses
- Moderate symptoms (agitation, confusion, hallucinations, ECG changes): occur above 300 mg
- Severe symptoms (delirium, seizures, coma): occur above 1,000 mg
While 50 mg of doxylamine (two Unisom tablets) is below these severe toxicity thresholds, it doubles exposure to anticholinergic effects without proven additional benefit.
Anticholinergic Burden
First-generation antihistamines carry significant risks:
- Daytime sedation and cognitive impairment
- Increased fall risk, particularly in older adults
- Potential association with dementia with chronic use 5
- Cardiac effects including tachycardia and potential arrhythmias 6
Clinical Pitfalls to Avoid
- Do not recommend doubling OTC sleep aid doses - The FDA-approved single-tablet dose represents the risk-benefit threshold
- Avoid chronic use - Tolerance develops rapidly, making continued use ineffective 3
- Consider better alternatives - If one tablet is ineffective, the patient needs proper evaluation for chronic insomnia, not dose escalation
- Watch for misuse - Patients may self-escalate doses seeking better sleep, increasing toxicity risk without benefit
What to Do Instead
If a single Unisom tablet is ineffective:
- Evaluate for chronic insomnia disorder requiring cognitive behavioral therapy for insomnia (CBT-I), which is first-line treatment 5
- Consider FDA-approved hypnotics if pharmacotherapy is needed: eszopiclone, zolpidem, zaleplon, or suvorexant have better evidence 2
- Reassess in 7-10 days - The FDA recommends further evaluation if insomnia doesn't resolve within this timeframe 5
The evidence is clear: stick to the FDA-approved single-tablet dose, and if ineffective, pursue appropriate insomnia evaluation rather than dose escalation.